HBsAg定量检测对聚乙二醇干扰素治疗慢性乙型肝炎效果的预测价值

张海月; 周培; 龚作炯

doi:10.3969/j.issn.1001-5256.2016.05.041

HBsAg定量检测对聚乙二醇干扰素治疗慢性乙型肝炎效果的预测价值

DOI: 10.3969/j.issn.1001-5256.2016.05.041

武汉大学人民医院感染病科

详细信息

中图分类号: R512.62
计量
- 文章访问数: 2765
- HTML全文浏览量: 38
- PDF下载量: 477
- 被引次数: 0
出版历程
- 出版日期: 2016-05-20

Predictive value of HBs Ag quantification in pegylated interferon therapy for chronic hepatitis B

摘要

摘要: 抗病毒治疗是慢性乙型肝炎（CHB）治疗的关键。聚乙二醇干扰素（PEG-IFN）兼有抗病毒和免疫调节作用,停药后可使30%40%患者发生HBe Ag血清学转换实现持续病毒学应答。许多研究表明HBs Ag定量可作为PEG-IFN抗HBV疗效预测指标,以及停药后持久免疫控制的预测指标。综述了PEG-IFN在CHB抗病毒治疗前、治疗过程中及治疗结束时HBs Ag水平与抗病毒治疗的关系,以阐明HBs Ag定量监测对PEG-IFN治疗CHB的意义,更好的指导和调整抗病毒治疗方案。
- 肝炎,乙型,慢性 /
- 肝炎表面抗原,乙型 /
- 干扰素类 /
- 预测 /
- 综述
Abstract: Antiviral therapy is the most important thing in the treatment of chronic hepatitis B( CHB). Pegylated interferon( PEG- IFN)has both antiviral and immunomodulatory effects,and after drug withdrawal,30%- 40% of patients can achieve HBe Ag seroconversion and sustained virologic response. Many studies have shown that HBs Ag quantification can be used as an index to predict the anti- HBV effect of PEG- IFN and sustained immune control after drug withdrawal. This article reviews the relationship between HBs Ag levels before,during,and after PEG- IFN therapy and antiviral effect to clarify the significance of HBs Ag quantification in the PEG- IFN treatment of CHB and to guide the regimen of antiviral therapy.
- hepatitis B,chronic /
- hepatitis B /
- surface antigens /
- interferons /
- forecasting

HTML全文

参考文献(30)

[1]BUSTER EH,FLINK HJ,CAKALOGLU Y,et al.Sustained HBeAg and HBsAg loss after long-term follow up of HBeAg-positive patients treated with peginterferon a-2b[J].Gastroenterology,2008,135(2):459-467.

[2] LAU GK,PIRATVISUTH T,LUO KX,et al.Peginterferon alfa-2a,lamivudine,and the combination for HBeAg-positive chronic hepatitis B[J].N Engl J Med,2005,352(26):2682-2695.

[3]WONG GH,YIU KL,WONG VS,et al.Meta-analysis:reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B[J].Aliment Pharmacol Ther,2010,32(9):1059-1068.

[4]MARCELLIN P,BONINO F,YURDAYDIN C,et al.Hepatitis B surface antigen levels:association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients[J].Hepatol Int,2013,7(1):88-97.

[5]REIJNDERS JG,RIJCKBORST V,SONNEVELD MJ,et al.Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir[J].J Hepatol,2011,54(3):449-454.

[6]DIENSTAG JL.Hepatitis B virus infection[J].N Engl J Med,2008,359(14):1486-1500.

[7]JAROSZEWICZ J,CALLE SB,WURSTHORN K,et al.Hepatitis B surface antigen(HBsA g)levels in the natural history of hepatitis B virus(HBV)-infection:a European perspective[J].J Hepatol,2010,52(4):514-522.

[8]CHEN LY,WANG GQ.Significance of HBsA g quantitation in antiviral therapy[J/CD].Chin J Front Med Sci:Electronic Version,2013,5(7):15-18.(in Chinese)陈力元,王贵强.乙型肝炎表面抗原定量在抗病毒治疗中的意义[J/CD].中国医学前沿杂志:电子版,2013,5(7):15-18.

[9]BOURNE EJ,DIENSTAG JL,LOPEZ VA,et al.Quantitative analysis of HBV cccD NA from clinical specimens:correlation with clinical and virological response during antiviral therapy[J].J Viral Hepat,2007,14(1):55-63.

[10]CHAN HL,THOMPSON A,MARTINOT PM,et al.Hepatitis B surface antigen quantification:why and how to use it in 2011-a core group report[J].J Hepatol,2011,55(5):1121-1131.

[11]NGUYEN T,THOMPSON AJ,BOWDEN S,et al.Hepatitis B surface antigen levels during the natural history of chronic hepatitis B:a perspective on Asia[J].J Hepatol,2010,52(4):508-513.

[12]WONG VW,WONG GL,YAN KK,et al.Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigenpositive chronic hepatitis B[J].Hepatology,2010,51(6):1945-1953.

[13]TANGKIJVANICH P,KOMOLMIT P,MAHACHAI V,et al.Low pretreatment serum HBsA g level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B[J].J Clin Virol,2009,46(2):117-123.

[14]TAKKENBERG B,ZAAIJER HL,de NIET A,et al.Baseline HBsA g level and on-treatment HBsA g and HBV DNA decline predict sustained virological response in HBeAg-negative chronic hepatitis B patients treated with peginterferon alfa-2a(Pegasys)and Adefovir(Hepsera);an interim analysis[J].Hepatology,2009,50:491.

[15]Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.

[16]JANSSEN HL,van ZONNEVELD M,SENTURK H,et al.Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeA g-positive chronic hepatitis B:a randomized trial[J].Lancet,2005,365(9454):123-129.

[17]SONNEVELD MJ,RIJCKBORST V,BOUCHER CA,et al.Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline[J].Hepatology,2010,52(4):1251-1257.

[18]KARAYIANNIS P.Serum hepatitis B surface antigen levels and their utility as a predictor of sustained virological response after antiviral treatment[J].Hepat Mon,2012,12(7):420-422.

[19]CHAN HL,WONG VW,CHIM AM,et al.Serum HBsA g quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B[J].Aliment Pharmacol Ther,2010,32(11-12):1323-1331.

[20]LAU G,MARCELLIN P,BRUNETTO M,et al.On-treatment monitoring of HBsA g levels to predict response to peginterferon alfa-2 in patients with HBeA g-positive chronic hepatitis B[J].J Hepatol,2009,50(9):s333.

[21]MARCELLIN P,BONINO F,LAU GK,et al.Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a[J].Gastroenterology,2009,136(7):2169-2179.

[22] MARCELLIN P,LAU GK,BONINO F,et al.Peginterferon alfa-2a alone,lamivudine alone,and the two in combination in patients with HBeA gnegative chronic hepatitis B[J].N Engl J Med,2004,351(12):1206-1217.

[23]RIJCKBORST V,ter BORG MJ,CAKALOGLU Y,et al.A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeA g-negative chronic hepatitis B[J].Am J Gastroenterol,2010,105(8):1762-1769.

[24]MOUCARI R,MARTINOT-PEIGNOUX M,MACKIEWICZ V,et al.Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha-2a[J].Antivir Ther,2009,14(8):1183-1188.

[25]MARCELLIN P,PIRATVISUTH T,BRUNETTO M,et al.Ontreatment decline in serum HBsA g levels predicts sustained immune control 1 year post-treatment and subsequent HBsA g clearance in HBeA g-negative hepatitis B virus-infected patients treated with peginterferon alfa-2a[J].Hepatol Int,2010,4:151.

[26]RIJCKBORST V,HANSEN B,FERENCI P,et al.Early ontreatment HBsA g and HBV DNA levels identify HBeA gnegative patients not responding to 48 or 96 weeks of peginterferon alfa-2a therapy[J].Hepatology,2010,52(2):557-558.

[27]JANSSEN HLA,KERHOF-LOS CJ,HEIJTINK RA,et al.Measurement of HBsA g to monitor hepatitis B viral replication in patients on a-interferon therapy[J].Antivir Res,1994,23(3-4):251-257.

[28]BRUNETTO MR,MORICONI F,BONINO F,et al.Hepatitis B virus surface antigen levels:a guide to sustained response to peginterferon alfa-2a in HBeA g-negative chronic hepatitis B[J].Hepatology,2009,49(4):1141-1150.

[29]LIU MH,CHEN QY,TIM J,et al.The correlation between serum HBsA g levels and viral loads depends upon wild-type and mutated HBV squences rather than the HBeA g/anti-HBe status[J].J Med Virol,2015,87(8):1351-1360.

[30]SHWETA PK,PREETI RM,SUPRIY MP,et al.Hepatitis B virus(HBV)infection in liver disease patients in mumbai,India with special reference to hepatitis B surface antigen(HBsA g)mutant detection[J].J Clin Diagn Res,2014,8(3):19-21.

施引文献

资源附件(0)

访问统计